Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy

Vaccine

Volumn 32, Issue 43, 2014, Pages 5703-5714

  Jackson, Ronald J ^a   Worley, Matthew ^a   Trivedi, Shubhanshi ^a   Ranasinghe, Charani ^a  

^a Biology and Environment   (Australia)

Author keywords

CD8+ T cell avidity; HIV vaccines; IgG1 and IgG2a; IL 13Ra2 adjuvanted vaccines; IL 4R antagonist; Mucosal systemic immunity

Indexed keywords

FOWLPOX VIRUS HUMAN IMMUNODEFICIENCY VIRUS VACCINE; FOWLPOX VIRUS HUMAN IMMUNODEFICIENCY VIRUS VACCINE INTERLEUKIN 13RECEPTORALPHA2DELTA10; FOWLPOX VIRUS HUMAN IMMUNODEFICIENCY VIRUS VACCINE INTERLEUKIN 4C118; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR TYPE I; INTERLEUKIN 4 RECEPTOR TYPE II; PROTEIN P55; TUMOR NECROSIS FACTOR ALPHA; TYROSINE; UNCLASSIFIED DRUG; VACCINIA VIRUS HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VACCINIA VIRUS HUMAN IMMUNODEFICIENCY VIRUS VACCINE INTERLEUKIN 13RECEPTORALPHA2DELTA10; VACCINIA VIRUS HUMAN IMMUNODEFICIENCY VIRUS VACCINE INTERLEUKIN 4C118; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4 RECEPTOR; P55 GAG PRECURSOR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEIN PRECURSOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; DELETION MUTANT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BLOOD; GENE REARRANGEMENT; HIV INFECTIONS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-13; INTERLEUKIN-2; INTERLEUKIN-4; MICE, INBRED BALB C; PROTEIN PRECURSORS; RECEPTORS, INTERLEUKIN-4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908447142     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.023     Document Type: Article

References (80)

1. Isaacs S.N. A stimulating way to improve T cell responses to poxvirus-vectored vaccines. J Clin Invest 2011, 121:19-21.
2. Virgin H.W., Walker B.D. Immunology and the elusive AIDS vaccine. Nature 2010, 464:224-231.
3. Cohen J. AIDS research. More woes for struggling HIV vaccine field. Science 2013, 340:667.
4. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220. [Epub 2009 October 20].
5. Gorse G.J., Patel G.B., Belshe R.B. HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers. AIDS Res Hum Retroviruses 2001, 17:1175-1189.
6. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671. Epub 2006 Nov 3.
7. Karnasuta C., Paris R.M., Cox J.H., Nitayaphan S., Pitisuttithum P., Thongcharoen P., et al. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005, 23:2522-2529.
8. Karasavvas N., Billings E., Rao M., Williams C., Zolla-Pazner S., Bailer R.T., et al. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 2012, 28:1444-1457.
9. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.
10. Rolland M., Edlefsen P.T., Larsen B.B., Tovanabutra S., Sanders-Buell E., Hertz T., et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012, 490:417-420.
11. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789.
12. Ferre A.L., Hunt P.W., Critchfield J.W., Young D.H., Morris M.M., Garcia J.C., et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009, 113:3978-3989. [Epub 2008 December 23].
13. Chen H., Ndhlovu Z.M., Liu D., Porter L.C., Fang J.W., Darko S., et al. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol 2012, 13:691-700.
14. Veazey R.S., DeMaria M., Chalifoux L.V., Shvetz D.E., Pauley D.R., Knight H.L., et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998, 280:427-431.
15. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
16. Belyakov I.M., Kuznetsov V.A., Kelsall B., Klinman D., Moniuszko M., Lemon M., et al. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 2006, 107:3258-3264.
17. Belyakov I.M., Isakov D., Zhu Q., Dzutsev A., Berzofsky J.A. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. J Immunol 2007, 178:7211-7221.
18. Belyakov I.M., Ahlers J.D., Nabel G.J., Moss B., Berzofsky J.A. Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology 2008, 381:106-115. [Epub 2008 September 14].
19. Kent S.J., Dale C.J., Ranasinghe C., Stratov I., De Rose R., Chea S., et al. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIV(SF162P3). Vaccine 2005, 23:5009-5021.
20. Ranasinghe C., Medveczky J.C., Woltring D., Gao K., Thomson S., Coupar B.E.H., et al. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic Iimmunity against HIV-1. Vaccine 2006, 24:5881-5895.
21. Ranasinghe C., Turner S.J., McArthur C., Sutherland D.B., Kim J.H., Doherty P.C., et al. Mucosal HIV-1 pox virus prime-boost immunization Induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. J Immunol 2007, 178:2370-2379.
22. Ranasinghe C., Ramshaw I.A. Immunisation route-dependent expression of IL-4/IL-13 can modulate HIV-specific CD8(+) CTL avidity. Eur J Immunol 2009, 39:1819-1830.
23. Ranasinghe C., Trivedi S., Stambas J., Jackson R.J. Unique IL-13Ralpha2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8(+) T-cell avidity and protective immunity. Mucosal Immunol 2013, 6:1068-1080.
24. Tabata Y., Khurana Hershey G.K. IL-13 receptor isoforms: breaking through the complexity. Curr Allergy Asthma Rep 2007, 7:338-345.
25. Luzina I.G., Keegan A.D., Heller N.M., Rook G.A., Shea-Donohue T., Atamas S.P. Regulation of inflammation by interleukin-4: a review of "alternatives". J Leukoc Biol 2012, 92:753-764.
26. Fichtner-Feigl S., Strober W., Kawakami K., Puri R.K., Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006, 12:99-106. [Epub 2005 December 4].
27. Ahlers J.D., Belyakov I.M., Terabe M., Koka R., Donaldson D.D., Thomas E.K., et al. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc Natl Acad Sci U S A 2002, 99:13020-13025.
28. Morrison B.W., Leder P. A receptor binding domain of mouse interleukin-4 defined by a solid-phase binding assay and in vitro mutagenesis. J Biol Chem 1992, 267:11957-11963.
29. Tomkinson A., Duez C., Cieslewicz G., Pratt J.C., Joetham A., Shanafelt M.C., et al. A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J Immunol 2001, 166:5792-5800.
30. Grunewald S.M., Kunzmann S., Schnarr B., Ezernieks J., Sebald W., Duschl A. A murine interleukin-4 antagonistic mutant protein completely inhibits interleukin-4-induced cell proliferation, differentiation, and signal transduction. J Biol Chem 1997, 272:1480-1483.
31. Tony H.P., Shen B.J., Reusch P., Sebald W. Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. Eur J Biochem 1994, 225:659-665.
32. Mata M., Travers P.J., Liu Q., Frankel F.R., Paterson Y. The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J Immunol 1998, 161:2985-2993.
33. Harrison J.M., Bertram E.M., Boyle D.B., Coupar B.E., Ranasinghe C., Ramshaw I.A. 4-1BBL coexpression enhances HIV-specific CD8 T cell memory in a poxvirus prime-boost vaccine. Vaccine 2006, 24:6867-6874.
34. Coupar B.E., Andrew M.E., Boyle D.B. A general method for the construction of recombinant vaccinia viruses expressing multiple foreign genes. Gene 1988, 68:1-10.
35. Heine H.G., Boyle D.B. Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens. Arch Virol 1993, 131:277-292.
36. Jackson R.J., Boyle D.B., Ranasinghe C. Heterologous prime-boost regimens in DNA vaccination. DNA vaccines, methods in molecular biology 2014, Springer. M. Rinaldi, D. Fioretti, S. Iurescia (Eds.).
37. Coupar B.E.H., Purcell D.F.J., Thomson S.A., Ramshaw I.A., Kent S.J., Boyle D.B. Fowlpox virus vaccines for HIV and SIV clinical and pre-clinical trials. Vaccine 2006, 24:1378-1388.
38. Boyle D.B., Anderson M.A., Amos R., Voysey R., Coupar B.E. Construction of recombinant fowlpox viruses carrying multiple vaccine antigens and immunomodulatory molecules. Biotechniques 2004, 37(104-6):8-11.
39. Cukalac T., Moffat J.M., Venturi V., Davenport M.P., Doherty P.C., Turner S.J., et al. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus. Vaccine 2009, 27:6755-6761. [Epub 2009 September 8].
40. Ranasinghe C., Eyers F., Stambas J., Boyle D.B., Ramshaw I.A., Ramsay A.J. A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations. Vaccine 2011, 29:3008-3020.
41. Xi Y., Day S.L., Jackson R.J., Ranasinghe C. Role of novel type I interferon epsilon in viral infection and mucosal immunity. Mucosal Immunol 2012, 5(6):610-622.
42. Trivedi S., Jackson R.J., Ranasinghe C. Interleukin-3 and granulocyte-macrophage colony-stimulating factor expression, a biomarker of memory CD8+ T cell immunity and vaccine efficacy. J Vaccines Vaccin 2013, 3:1000166. (open access journal).
43. La Gruta N.L., Turner S.J., Doherty P.C. Hierarchies in cytokine expression profiles for acute and resolving influenza virus-specific CD8+ T cell responses: correlation of cytokine profile and TCR avidity. J Immunol 2004, 172:5553-5560.
44. Ranasinghe C., Ramshaw I.A. Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity. Expert Rev Vaccines 2009, 8:1171-1181.
45. Almeida J.R., Price D.A., Papagno L., Arkoub Z.A., Sauce D., Bornstein E., et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007, 204:2473-2485. [Epub 2007 September 24].
46. Harari A., Bart P.A., Stohr W., Tapia G., Garcia M., Medjitna-Rais E., et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008, 205:63-77. [Epub 2008 January 14].
47. Burgers W.A., Chege G.K., Muller T.L., van Harmelen J.H., Khoury G., Shephard E.G., et al. Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. J Gen Virol 2009, 90:468-480.
48. Berger C.T., Frahm N., Price D.A., Mothe B., Ghebremichael M., Hartman K.L., et al. High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J Virol 2011, 85:9334-9345.
49. Bihl F., Frahm N., Di Giammarino L., Sidney J., John M., Yusim K., et al. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 2006, 176:4094-4101.
50. Wijesundara D.K., Tscharke D.C., Jackson R.J., Ranasinghe C. Reduced interleukin-4 receptor alpha expression on CD8+ T cells correlates with higher quality anti-viral immunity. PLOS ONE 2013, 8:e55788.
51. Wijesundara D.K., Jackson R.J., Tscharke D.C., Ranasinghe C. IL-4 and IL-13 mediated down-regulation of CD8 expression levels can dampen anti-viral CD8 T cell avidity following HIV-1 recombinant pox viral vaccination. Vaccine 2013, 2013:1048-1057.
52. Bembridge G.P., Lopez J.A., Cook R., Melero J.A., Taylor G. Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon. J Virol 1998, 72:4080-4087.
53. Jackson R.J., Ramsay A.J., Christensen C.D., Beaton S., Hall D.F., Ramshaw I.A. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001, 75:1205-1210.
54. Alexander-Miller M.A., Leggatt G.R., Berzofsky J.A. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A 1996, 93:4102-4107.
55. Taub D.D., Ershler W.B., Janowski M., Artz A., Key M.L., McKelvey J., et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med 2008, 121:1058-1064.
56. Leong K.H., Ramsay A.J., Boyle D.B., Ramshaw I.A. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol 1994, 68:8125-8130.
57. Dale C.J., De Rose R., Wilson K.M., Croom H.A., Thomson S., Coupar B.E., et al. Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12. Vaccine 2004, 23:188-197.
58. French M.A., Center R.J., Wilson K.M., Fleyfel I., Fernandez S., Schorcht A., et al. Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to 'protective' human leukocyte antigen-B alleles in HIV controllers. AIDS 2013, 27:519-528.
59. Isitman G., Chung A.W., Navis M., Kent S.J., Stratov I. Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 2011, 412:110-116.
60. Girard M.P., Picot V., Longuet C., Nabel G.J. Report of the Cent Gardes HIV Vaccine Conference: the B-cell response to HIV. Part 2: non-neutralizing antibodies: Fondation Merieux Conference Center, Veyrier du Lac, France 5-7 November 2012. Vaccine 2013, 31:2984-2987.
61. Machmach K., Leal M., Gras C., Viciana P., Genebat M., Franco E., et al. Plasmacytoid dendritic cells reduce HIV production in elite controllers. J Virol 2012, 86:4245-4252.
62. Barblu L., Machmach K., Gras C., Delfraissy J.F., Boufassa F., Leal M., et al. Plasmacytoid dendritic cells (pDCs) from HIV controllers produce interferon-alpha and differentiate into functional killer pDCs under HIV activation. J Infect Dis 2012, 206:790-801.
63. Snapper C.M., Paul W.E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987, 236:944-947.
64. Markine-Goriaynoff D., van der Logt J.T., Truyens C., Nguyen T.D., Heessen F.W., Bigaignon G., et al. IFN-gamma-independent IgG2a production in mice infected with viruses and parasites. Int Immunol 2000, 12:223-230.
65. Tait Wojno E.D., Artis D. Innate lymphoid cells: balancing immunity, inflammation, and tissue repair in the intestine. Cell Host Microbe 2012, 12:445-457.
66. Spits H., Di Santo J.P. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011, 12:21-27.
67. Nussbaum J.C., Van Dyken S.J., von Moltke J., Cheng L.E., Mohapatra A., Molofsky A.B., et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature 2013, 502:245-248.
68. Licona-Limon P., Kim L.K., Palm N.W., Flavell R.A. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 2013, 14:536-542.
69. Walker J.A., Barlow J.L., McKenzie A.N. Innate lymphoid cells - how did we miss them?. Nat Rev Immunol 2013, 13:75-87.
70. Monticelli L.A., Sonnenberg G.F., Abt M.C., Alenghat T., Ziegler C.G., Doering T.A., et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 2011, 12:1045-1054.
71. Paul W.E., Zhu J. How are T(H)2-type immune responses initiated and amplified?. Nat Rev Immunol 2010, 10:225-235.
72. Lee Y.J., Holzapfel K.L., Zhu J., Jameson S.C., Hogquist K.A. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat Immunol 2013, 14:1146-1154.
73. Smith G.L., Benfield C.T., Maluquer de Motes C., Mazzon M., Ember S.W., Ferguson B.J., et al. Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J Gen Virol 2013, 94:2367-2392.
74. Symons J.A., Alcami A., Smith G.L. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 1995, 81:551-560.
75. Alcami A., Smith G.L. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 1995, 69:4633-4639.
76. Alcami A., Khanna A., Paul N.L., Smith G.L. Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. J Gen Virol 1999, 80(Pt 4):949-959.
77. Born T.L., Morrison L.A., Esteban D.J., VandenBos T., Thebeau L.G., Chen N., et al. A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell response. J Immunol 2000, 164:3246-3254.
78. Wang Y., Chaudhri G., Jackson R.J., Karupiah G. IL-12p40 and IL-18 play pivotal roles in orchestrating the cell-mediated immune response to a poxvirus infection. J Immunol 2009, 183:3324-3331. [Epub 2009 August 5].
79. Falivene J., Del Medico Zajac M.P., Pascutti M.F., Rodriguez A.M., Maeto C., Perdiguero B., et al. Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS ONE 2012, 7:e32220.
80. Trivedi S, Jackson RJ, Ranasinghe C. Different HIV pox viral vector-based vaccines and adjuvants can induce unique antigen presenting cells that modulate CD8 T cell avidity. (Submitted-in revision).